Lundbeck will supply Russia with medicine for as long as sanctions allow

As long as Lundbeck is able to supply drugs to patients in Russia under current sanctions, the pharmaceutical firm will do so, says Chief Commercial Officer Jacob Tolstrup.

Jacob Tolstrup., Chief Commercial Officer at Lundbeck | Photo: PR / Lundbeck

Despite Russia’s invasion of neighboring country Ukraine, which has resulted in extensive sanctions against the aggressor from the Western world, Danish pharmaceutical firm Lundbeck will continue its activities there.

”As a pharmaceutical company, we believe we have an obligation to those patients who need our medications – these for example include people suffering from schizophrenia, depression and anxiety. This is also why drugs are usually exempted from sanctions,” Chief Commercial Officer at Lundbeck Jacob Tolstrup tells MedWatch, in a written comment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs